RxDataLab Platform

Every clinical trial change, automatically detected.

ClinicalTrials.gov doesn't notify you when a trial changes. We monitor every registered biotech trial daily and surface what changed: endpoint modifications, enrollment shifts, arm updates, and stopped trials. Organized by company.

$499/mo

Cancel anytime. Access continues through the end of the billing period.

450K+ trials monitored
500+ biotech companies tracked
Daily comparison against ClinicalTrials.gov
4 change categories detected

Detected this week

Recent trial changes caught automatically from ClinicalTrials.gov.

Updated May 4, 2026

Novartis NVS Mar 28
NCT06031844 PHASE2 Endpoint

The primary endpoint was changed from measuring serum levels of IL-6 and IL-18 to specifically measuring the ratio to baseline serum levels of IL-18 and IL-6 for DFV890 based on an Emax model. This represents a more specific and model-driven approach to assessing the drug's effect on these biomarkers. The secondary endpoint was also refined to specify trough plasma concentration (Ctrough) at specific pre-dose time points.

AMGEN INC AMGN Mar 28
NCT04303780 PHASE3 Update

Completion date: 2026-02-25 → 2026-05-29

HUTCHMED (China) Ltd HCM Mar 28
NCT04762602 PHASE1 Update

Trial stopped: The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns

Every item links to the original ClinicalTrials.gov record on the platform.

Trial monitoring

Trials can quietly change, don't miss it

Daily comparison against ClinicalTrials.gov. Every endpoint modification, enrollment shift, and status change categorized and summarized automatically.

NCT04762602

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Terminated Phase 1

HUTCHMED (China) Ltd HCM

Enrollment

42

Primary Completion

2025-02

Detected

Mar 28, 2026

Endpoint modification detected automatically

Primary endpoint timeframe

From the first dose of the study drug to 37 days after the last dose of study drug
+ From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

Primary endpoint timeframe

Up to 28 days after first dose of study drug
+ From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

Secondary endpoint 1 timeframe

PK weeks at screening through safety follow-up, assessed up to 36 months
+ Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1

Secondary endpoint 2 timeframe

From first dose of study drug to the time of progressive disease, assessed up to 36 months
+ Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

+ 5 more endpoints modified

AI Summary

A new primary endpoint, Recommended Phase 2 Dose (RP2D) of HMPL-306, was added. The primary endpoint 'Frequency and severity of AEs' was rephrased to 'Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)' with a slightly extended timeframe. The secondary endpoint 'Clinical Benefit Rate (CBR)' was replaced with 'Disease Control Rate (DCR)' and a new secondary endpoint, 'Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)', was added. Additionally, 'Time to Response (TTR)' was added as a new secondary endpoint.

Full change history per trial. Every detection timestamped and linked to the original registry record.

Subscribe to access →

Change Detection

What gets caught.

ClinicalTrials.gov logs every update but doesn't surface them. We run a daily comparison and categorize every change.

Endpoint

Endpoint Modifications

Primary and secondary endpoint changes, new outcome measures added or removed, assessment timepoints shifted.

Enrollment

Enrollment Changes

Target enrollment updated, eligibility criteria modified, new sites added, age range or inclusion/exclusion criteria changed.

Status

Status Shifts

Recruiting, suspended, terminated, completed. Caught the day the registry updates. Stopped trials flagged immediately.

Study Arm

Study Arms

Arms added or dropped, dosing changes, new intervention branches, comparator updates across multi-arm studies.

Company Pipeline View

Trials organized by company.

Every company mapped to their complete pipeline. Trials with recent changes flagged automatically. Sample from Solid Biosciences Inc. (SLDB).

Solid Biosciences Inc. SLDB

4 recruiting
1 Phase 3
6 trials shown
Phase 1 ● Recruiting Recently updated

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (...

NCT07148089 · 18 enrolled

Phase 3 ● Recruiting

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT...

NCT07160634 · 80 enrolled

Phase 1/2 ● Recruiting

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT06138639 · 60 enrolled

Phase 1 ● Recruiting

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355 · 10 enrolled

Pipeline View

Every company's full trial pipeline in one view

500+ biotech companies mapped to their complete clinical trial pipelines. Every Phase 1 through Phase 3 trial, linked to the company, not buried under NCT IDs. See exactly where each program is, what changed recently, and what's running in parallel.

Change History

Changes buried in ClinicalTrials.gov sponsor updates, surfaced automatically

Catch every endpoint modifications, enrollment count changes, or new arm added or dropped. Status changes from recruiting to suspended. We run a daily comparison against the registry and log every update, categorized, timestamped, and linked to the original record. Complete change history per trial.

app.rxdatalab.com

What's included.

Clinical trial tracking is one part of a broader platform built for BD, investors, and strategy teams who work from primary sources.

Monitor trial changes automatically

Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Don't miss a thing.

Track a company's complete pipeline

500+ biotech companies mapped to their trials. Every Phase 1 through NDA, organized by company rather than NCT ID. Every item links to the original registry record.

Hedge fund positioning in biotech

13D/G ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.

See live data sample →

SEC filings classified by event type

8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or type.

See live data sample →

Map competitive landscapes by indication

Search any indication. Every industry trial mapped using NLM's MeSH ontology. Overlay recent trial events across the competitive field.

Projects and notes that stay with the data

Company and trial watchlists. Timestamped notes on trial and company pages. Dashboard shows what changed across your coverage since your last session.

Pricing

Simple, transparent pricing.

Individual — Monthly

$499/mo

Billed monthly. Cancel anytime from your account page.

  • Full platform access
  • BioHedge (13D/G fund positioning)
  • Clinical trial change detection
  • 8-K signal detection
  • Competitive landscape mapping
  • Research workspace and notes
Subscribe Now →

Teams & Institutions

Custom pricing

For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.

  • Multi-seat access
  • Custom data coverage and exports
  • Invoiced billing and enterprise contracts
  • API access and custom data feeds
  • Dedicated support

or email [email protected]

What happens after payment?

You'll receive a welcome email with a link to set your password. Access immediately once your password is set.

How do I cancel?

Go to your account page and click "Manage Billing." Access continues through the end of your billing period.

Do you offer trials or demos?

The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.

Questions or enterprise pricing?

Email [email protected] for team access, institutional pricing, or anything else.

By subscribing you agree to our Terms of Service and Data License Agreement.